Acute Myeloid Leukemia | Topics

NGS May Play an Important Role in Helping Select Targeted Therapies in Extramedullary AML
September 21, 2022

Frequent targetable mutations in patients with extramedullary acute myeloid leukemia lends credence to the use of next-generation sequencing to determine the optimal targeted therapy approach.

Tumor Lysis Syndrome Incidence Uncommon in Venetoclax Treatment for AML
September 15, 2022

In patients with acute myeloid leukemia receiving venetoclax, tumor lysis syndrome was uncommon; patients at high risk should be admitted for venetoclax dosing ramp-up.

Phase 1 Study Assessing BRG1/BRM Inhibitor FHD-286 in Relapsed/Refractory AML/MDS Receives Full Clinical Hold From FDA
August 29, 2022

The FDA has placed a full clinical hold on a phase 1 trial assessing FHD-286 as a potential treatment for patients with relapsed/refractory acute myelogenous leukemia and myelodysplastic syndrome due to concerns around suspected cases of fatal differentiation syndrome that may be associated with the agent.

EMA Accepts Marketing Authorization Application for Decitabine and Cedazuridine in Adult AML
August 24, 2022

Adult patients with acute myeloid leukemia who are not eligible for treatment with standard induction chemotherapy may benefit from treatment with decitabine and cedazuridine, the marketing authorization application for which was accepted by the European Medicines Agency.

Venetoclax Schedule Modifications Linked to Longer OS in Real-World Newly Diagnosed AML
August 15, 2022

Patients with newly diagnosed acute myeloid leukemia had longer overall survival with a modified dosing schedule of venetoclax plus a hypomethylating agent.

Pre-HSCT WT1 Levels Vs ELN 2017 Risk Classification Is a Better Predictor of Outcomes in Intermediate-Risk AML
July 20, 2022

Although European Leukemia Net 2017 Risk Stratification was ineffective for predicting outcomes following allogeneic hematopoietic stem cell transplantation in intermediate-risk acute myeloid leukemia, pre-transplant Wilms tumor gene 1 expression and FLT3-ITD mutation demonstrated promising predictive ability.

Black Adolescent Young Adults With AML Have Worse Outcomes Vs White Population
July 08, 2022

Black adolescent young adult patients with acute myeloid leukemia appeared to have inferior outcomes compared with White patients.

Similar OS and Transplantation Observed With Decitabine vs Chemo in Geriatric AML
June 20, 2022

Older patients with acute myeloid leukemia who were treated with decitabine experienced comparable outcomes vs daunorubicin and cytarabine.

Quizartinib Added to Chemo Boosts Overall Survival in FLT3-ITD–positive AML
June 13, 2022

The combination of quizartinib plus chemotherapy yielded better survival outcomes vs chemotherapy alone in the frontline setting of FLT3-ITD-positive acute myeloid leukemia.

Ivosidenib Plus Azacitidine Yields Significant Treatment Benefit in IDH1-Mutant AML
June 04, 2022

Results from the phase 3 AGILE study show patients with IDH1-mutant acute myeloid leukemia had improved outcomes when treated with ivosidenib plus azacitidine vs placebo plus azacitidine.